PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics.
Newark, California–based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases.
According to a news release, Syneos Health recommended PhysIQ’s patient monitoring technology to help advance InCarda’s clinical study of InRhythm (orally inhaled flecainide) in patients with AFib.
The Phase III Restore-1 study uses wearable sensors and PhysIQ’s FDA-cleared AFib digital biomarker to capture real-world patient data in near-real-time. The goal is to accelerate the speed of pre-screening and enrollment of 400 patients in 100 clinical sites across Europe and North America.
“Speed is a critical factor throughout in this groundbreaking trial design,” PhysIQ CMO Dr. Steve Steinhubl said in the release. “Using wearable data transmission and our FDA-cleared algorithm to confirm AF symptoms, we can …